Skip to main content
Premium Trial:

Request an Annual Quote

And It Did Work

The New York Times has a Q&A with Brian Druker, the researcher who developed Gleevec. When Druker started out as an oncologist in the '80s, "cancer was seen as something like a light switch that was stuck in an 'on' position. You were given a baseball bat, which was chemotherapy, and told to knock the light out with the bat," he says. That led him to study how cell growth is regulated and, eventually, brought him to Gleevec, which is now used by about 200,000 people. "I understood that this project was too good to give up on. My patients needed me to do something to help them. I did everything I could by getting them a drug I thought would work," Druker says.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.